Hui, Vicki Wing-Ki
Au, Christopher Langjun
Lam, Amy Shuk Man
Yip, Terry Cheuk-Fung
Tse, Yee-Kit
Lai, Jimmy Che-To
Chan, Henry Lik-Yuen
Wong, Vincent Wai-Sun
Wong, Grace Lai-Hung http://orcid.org/0000-0002-2863-9389
Funding for this research was provided by:
Gilead Sciences (IN-HK-987-6069)
Article History
Received: 27 March 2022
Accepted: 9 July 2022
First Online: 8 September 2022
Declarations
:
: Terry Yip has served as an advisory committee member and a speaker for Gilead Sciences. Henry Chan is an advisor for AbbVie, Aligos, Aptorum, Arbutus, Hepion, Janssen, Gilead, GSK, Merck, Roche, Vaccitech, VenatoRx, Vir Biotechnology; and a speaker for Mylan, Gilead and Roche. Vincent Wong has served as an advisory committee member for 3 V-BIO, AbbVie, Allergan, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Janssen, Novartis, Novo Nordisk, Perspectum Diagnostics, Pfizer, TARGET-NASH and Terns; and a speaker for Bristol-Myers Squibb, Echosens, Gilead Sciences and Merck. He has also received a research grant from Gilead Sciences. Grace Wong has served as an advisory committee member for Gilead Sciences and Janssen, as a speaker for Abbott, Abbvie, Bristol-Myers Squibb, Echosens, Furui, Gilead Sciences, Janssen and Roche, and received research grant from Gilead Sciences. The other authors declare that they have no competing interests.
: The study protocol was approved by the Joint Chinese University of Hong Kong—New Territories East Cluster Clinical Research Ethics Committee.
: Not applicable.
: Because of the retrospective nature of this study and we will have no access to patient identifiers, written informed consent will be waived, subject to approval by the Joint CUHK-NTEC CREC.
: All the authors are consent to publish the data.
: Not available.